A case of Guillain–Barre syndrome following Pfizer COVID-19 vaccine
Since the first-reported case of Severe Acute Respiratory Distress Syndrome-Coronavirus 2 in December 2019, COVID-19 has caused a global pandemic associated with significant morbidity and mortality. After a year of advances in vaccine research and development, three vaccines for the prevention of CO...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Greater Baltimore Medical Center
2021-09-01
|
| Series: | Journal of Community Hospital Internal Medicine Perspectives |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/20009666.2021.1954284 |
| _version_ | 1797970425669484544 |
|---|---|
| author | Shiavax J. Rao Sahiba Khurana Gayathri Murthy Elliot T. Dawson Noushin Jazebi Christopher J. Haas |
| author_facet | Shiavax J. Rao Sahiba Khurana Gayathri Murthy Elliot T. Dawson Noushin Jazebi Christopher J. Haas |
| author_sort | Shiavax J. Rao |
| collection | DOAJ |
| description | Since the first-reported case of Severe Acute Respiratory Distress Syndrome-Coronavirus 2 in December 2019, COVID-19 has caused a global pandemic associated with significant morbidity and mortality. After a year of advances in vaccine research and development, three vaccines for the prevention of COVID-19 (manufactured by Pfizer, Moderna and Johnson & Johnson’s Janssen Biotech) are approved for use in the USA. We report the first case of Guillain–Barre Syndrome after receiving the second dose of the Pfizer COVID-19 vaccine, in a 42-year-old woman presenting with progressive ascending weakness and paresthesias. Diagnostic workup demonstrated cytoalbuminologic dissociation on cerebrospinal fluid analysis with confirmatory evidence of early demyelinating electrodiagnostic features on nerve conduction study and an extensive serological workup being negative for other viral or autoimmune disease triggers. Management included administration of intravenous immunoglobulin (total of 2 gm/kg), with frequent monitoring of forced vital capacity and negative inspiratory force. A longitudinal risk profile of neurologic complications caused from COVID-19 vaccines remains limited, and prompt recognition of potential neurological complications from the COVID-19 vaccine is of interest to public health. |
| first_indexed | 2024-04-11T03:16:34Z |
| format | Article |
| id | doaj.art-ebac4fd39e1c4a0e87a9bd081899fb9a |
| institution | Directory Open Access Journal |
| issn | 2000-9666 |
| language | English |
| last_indexed | 2024-04-11T03:16:34Z |
| publishDate | 2021-09-01 |
| publisher | Greater Baltimore Medical Center |
| record_format | Article |
| series | Journal of Community Hospital Internal Medicine Perspectives |
| spelling | doaj.art-ebac4fd39e1c4a0e87a9bd081899fb9a2023-01-02T10:13:41ZengGreater Baltimore Medical CenterJournal of Community Hospital Internal Medicine Perspectives2000-96662021-09-0111559760010.1080/20009666.2021.19542841954284A case of Guillain–Barre syndrome following Pfizer COVID-19 vaccineShiavax J. Rao0Sahiba Khurana1Gayathri Murthy2Elliot T. Dawson3Noushin Jazebi4Christopher J. Haas5MedStar Union Memorial HospitalMedStar Union Memorial HospitalMedStar Harbor HospitalMedStar Franklin Square Medical CenterGeorgetown University Medical CenterGeorgetown University Medical CenterSince the first-reported case of Severe Acute Respiratory Distress Syndrome-Coronavirus 2 in December 2019, COVID-19 has caused a global pandemic associated with significant morbidity and mortality. After a year of advances in vaccine research and development, three vaccines for the prevention of COVID-19 (manufactured by Pfizer, Moderna and Johnson & Johnson’s Janssen Biotech) are approved for use in the USA. We report the first case of Guillain–Barre Syndrome after receiving the second dose of the Pfizer COVID-19 vaccine, in a 42-year-old woman presenting with progressive ascending weakness and paresthesias. Diagnostic workup demonstrated cytoalbuminologic dissociation on cerebrospinal fluid analysis with confirmatory evidence of early demyelinating electrodiagnostic features on nerve conduction study and an extensive serological workup being negative for other viral or autoimmune disease triggers. Management included administration of intravenous immunoglobulin (total of 2 gm/kg), with frequent monitoring of forced vital capacity and negative inspiratory force. A longitudinal risk profile of neurologic complications caused from COVID-19 vaccines remains limited, and prompt recognition of potential neurological complications from the COVID-19 vaccine is of interest to public health.http://dx.doi.org/10.1080/20009666.2021.1954284guillain barre syndromecoronaviruscovid-19vaccinationpfizer |
| spellingShingle | Shiavax J. Rao Sahiba Khurana Gayathri Murthy Elliot T. Dawson Noushin Jazebi Christopher J. Haas A case of Guillain–Barre syndrome following Pfizer COVID-19 vaccine Journal of Community Hospital Internal Medicine Perspectives guillain barre syndrome coronavirus covid-19 vaccination pfizer |
| title | A case of Guillain–Barre syndrome following Pfizer COVID-19 vaccine |
| title_full | A case of Guillain–Barre syndrome following Pfizer COVID-19 vaccine |
| title_fullStr | A case of Guillain–Barre syndrome following Pfizer COVID-19 vaccine |
| title_full_unstemmed | A case of Guillain–Barre syndrome following Pfizer COVID-19 vaccine |
| title_short | A case of Guillain–Barre syndrome following Pfizer COVID-19 vaccine |
| title_sort | case of guillain barre syndrome following pfizer covid 19 vaccine |
| topic | guillain barre syndrome coronavirus covid-19 vaccination pfizer |
| url | http://dx.doi.org/10.1080/20009666.2021.1954284 |
| work_keys_str_mv | AT shiavaxjrao acaseofguillainbarresyndromefollowingpfizercovid19vaccine AT sahibakhurana acaseofguillainbarresyndromefollowingpfizercovid19vaccine AT gayathrimurthy acaseofguillainbarresyndromefollowingpfizercovid19vaccine AT elliottdawson acaseofguillainbarresyndromefollowingpfizercovid19vaccine AT noushinjazebi acaseofguillainbarresyndromefollowingpfizercovid19vaccine AT christopherjhaas acaseofguillainbarresyndromefollowingpfizercovid19vaccine AT shiavaxjrao caseofguillainbarresyndromefollowingpfizercovid19vaccine AT sahibakhurana caseofguillainbarresyndromefollowingpfizercovid19vaccine AT gayathrimurthy caseofguillainbarresyndromefollowingpfizercovid19vaccine AT elliottdawson caseofguillainbarresyndromefollowingpfizercovid19vaccine AT noushinjazebi caseofguillainbarresyndromefollowingpfizercovid19vaccine AT christopherjhaas caseofguillainbarresyndromefollowingpfizercovid19vaccine |